InMode Ltd.
No enriched coverage for $INMD in the last 7 days.
No SEC Form 4 filings for $INMD in the last 30 days.
See all $INMD insider activity →InMode Ltd. (Nasdaq: INMD) reported Q2 2026 GAAP revenues of $95.6M, unchanged vs Q2 2025. Consumables and service rose 13% to $22.3M. GAAP net income was $17.1M ($0.29/diluted share). Cash and equivalents plus marketable securities totaled $501.1M at June 30, 2026. FY2026 outlook: revenues $365M-$375M and non-GAAP EPS $1.29-$1.34.
InMode Ltd. (INMD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025 YOKNEAM, Israel, August 5, 2026 - InMode Ltd. (Nasdaq: INMD) (“InMode”) , a leading global provider of innovative medical techno
InMode Ltd. (NASDAQ: INMD) said its board received an unsolicited acquisition proposal from Steel Partners Holdings L.P., dated July 9, 2026. A special committee of independent directors will review the proposal with legal and financial advisors. The committee said it will not comment further for now.
Recent INMD coverage spans financial news, mergers & acquisitions and earnings.
Results were revenue-stable year over year but profitability declined, while FY guidance sets a clear earnings path for 2H 2026.
Earnings miss on revenue flatness and margin compression may pressure the stock.
The disclosure increases takeover optionality and can re-rate deal probability, but provides no terms or timing, limiting immediate valuation precision.
A competing, higher takeover bid plus governance and valuation disputes raise the odds of a bidding war and board process changes.
A shareholder-led buyout offer at a premium is a near-term catalyst that can drive spread compression and takeover-arb positioning.
alphai scores every news story that mentions INMD with an AI model for sentiment and relevance, and aggregates insider trades from InMode Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
InMode Ltd. (Nasdaq: INMD) reported Q2 2026 GAAP revenues of $95.6M, unchanged vs Q2 2025. Consumables and service rose 13% to $22.3M. GAAP net income was $17.1M ($0.29/diluted share). Cash and equivalents plus marketable securities totaled $501.1M at June 30, 2026. FY2026 outlook: revenues $365M-$375M and non-GAAP EPS $1.29-$1.34.
6 min readInMode Ltd. (INMD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025 YOKNEAM, Israel, August 5, 2026 - InMode Ltd. (Nasdaq: INMD) (“InMode”) , a leading global provider of innovative medical techno
2 min readInMode Ltd. (NASDAQ: INMD) said its board received an unsolicited acquisition proposal from Steel Partners Holdings L.P., dated July 9, 2026. A special committee of independent directors will review the proposal with legal and financial advisors. The committee said it will not comment further for now.
1 min readInMode Ltd (INMD) shares rose about 4% premarket after Steel Partners Holdings proposed to buy the medical aesthetics company for $16.75 per share in cash, a 20% premium to $13.95 and above a prior $16.20 bid by CEO Moshe Mizrahy. Steel Partners urged an independent committee, questioned governance and possible MNPI around share purchases, and cited 2026 adj. EBITDA of $65M vs guidance $73M-$78M.
4 min readInMode Ltd (NASDAQ:INMD) shares rose about 4% premarket after Steel Partners Holdings offered to buy the company for $16.75 per share in cash. Steel Partners, a major shareholder, cited a 20% premium to $13.95 and said it would allow rollover of up to 40% of equity into Steel-owned InMode. It urged an independent committee, challenged CEO Moshe Mizrahy, and referenced 2026 adjusted EBITDA of $65 million versus guidance of $73 million to $78 million.
4 min readInMode Ltd., a small-cap Pharmaceuticals & Biotechnology company, has plunged to a new 52-week low of $12.95, marking a 28.66% stock price drop over the past year. This decline follows five consecutive quarters of negative results, including a 67.35% fall in net profit and low operating cash flow. The company’s financial performance significantly underperforms the S&P 500, highlighting challenges in its financial landscape.
4 min readInMode (NASDAQ:INMD) shares gapped down following a prior closing price of $15.22, opening at $14.11, and last trading around $14.01. The company's recent earnings reported $0.46 EPS, beating consensus estimates, but revenue slightly missed expectations. Despite a consensus "Hold" rating from analysts with an average target price of $16.80, the stock has seen varied analyst adjustments, including a recent price target cut by UBS Group.
3 min readInMode (INMD) shares edged higher following reports that the company is exploring strategic options, including a potential sale. This news comes after the company's stock has faced significant declines over the past year.
2 min readThis article reports that Inmode shares rose following unconfirmed news that Steel Partners, a diversified holding company, had made an offer to acquire a majority stake in the aesthetic medicine device manufacturer. The news was first reported by Israeli news outlet Calcalist, though there was no official confirmation from either company.
2 min readImage source: The Motley Fool.Wednesday, Nov. 5, 2025 at 8:30 a.m. ETChairman and Chief Executive Officer - Moshe MizrahiContinue reading ...
3 min read
